How to make vaccines affordable

Beyond Biotech - the podcast from Labiotech

Among other things, UK-headquartered company Phenotypeca has been working with the Bill & Melinda Gates Foundation to produce albumin for low and middle-income countries to reduce the costs of vaccines.

The company’s CEO, Johnny Cordiner, and research and development director, Professor Ed Louis, tell us about the work, as well as the company and its other projects.

01:01-11:57: About Phenotypeca
11:57-14:04: What is recombinant protein technology?
14:04-16:39: What are the issues around the cost of albumin?
16:39-20:48: How can you help improve affordability?
20:48-26:55: What is QTL technology?
26:55-30:18: What are the benefits of this technology?
30:19-34:22: Partnering with the Bill & Melinda Gates Foundation
34:22-36:37: What’s the timeline?
36:37-39:45: What else are you working on?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Chapters

1. How to make vaccines affordable (00:00:00)

2. About Phenotypeca (00:01:01)

3. What is recombinant protein technology? (00:11:57)

4. What are the issues around the cost of albumin? (00:14:04)

5. How can you help improve affordability? (00:16:39)

6. What is QTL technology? (00:20:48)

7. What are the benefits of this technology?
 (00:26:55)

8. Partnering with the Bill & Melinda Gates Foundation (00:30:19)

9. What’s the timeline? (00:34:22)

10. What else are you working on? (00:36:37)